Business, energy, technology, markets and global industry news from Business News Today
PharmaDeviceNews
Representative image: Vistagen’s fasedienol Phase 3 trial highlights the growing search for rapid, as-needed nasal spray treatments for social anxiety disorder, especially in high-pressure public speaking and performance settings.
Pharma & Biotech

Why PALISADE-4 is a high-stakes test for Vistagen’s nose-to-brain anxiety drug strategy

Social anxiety needs faster options. Vistagen’s fasedienol now faces the Phase 3 test that could make or break its nasal-spray thesis.

Read More
Representative image of a child receiving a needle-free polio vaccine during a community immunisation campaign, highlighting PharmaJet’s Tropis system and Nigeria’s push to close vaccine coverage gaps.
Medical Devices & Diagnostics

Can PharmaJet’s needle-free Tropis system help Nigeria close its polio gap?

Nigeria has polio tools, but coverage gaps remain. PharmaJet’s Tropis campaign tests whether needle-free delivery can close the last mile.

Read More
Medical Devices & Diagnostics

Why Sensus Healthcare’s SkinCure resolution matters for superficial radiotherapy growth

Sensus settled the dispute, but the harder test is SRT adoption. Can reimbursement momentum turn into durable medtech growth?

Read More
Pharma & Biotech

Why Encompass Health is betting on a fast-growing Texas suburb before rivals crowd in

Haslet is growing fast. Encompass Health’s 50-bed rehab hospital shows healthcare real estate is chasing North Texas suburbia.

Read More
Pharma & Biotech

What Saban Community Clinic’s Crenshaw project reveals about urban healthcare deserts

South Los Angeles lacks reliable primary care. Saban Community Clinic’s Crenshaw center tests whether integrated care can close that gap.

Read More
Pharma & Biotech

Cryo-Cell avoided a delisting scare for now, but investors still face a 2027 countdown

Cryo-Cell avoided immediate delisting pressure. The harder test is whether its cord blood banking model can repair the balance sheet by 2027.

Read More
Representative image: Ensoma’s EN-374 clinical safety data highlight the growing promise of in vivo hematopoietic stem cell engineering for X-linked chronic granulomatous disease, as gene therapy developers test whether one-time treatments can move beyond complex ex vivo manufacturing and into scalable clinical use.
Pharma & Biotech

Ensoma’s EN-374 safety data open a new test for in vivo HSC engineering

In vivo gene therapy has reached human HSC engineering. Ensoma’s EN-374 safety data raise a bigger question: can durability follow?

Read More
Representative image of a clinician reviewing lung CT scans and noninvasive sputum-based testing, as bioAffinity Technologies reports rising CyPath Lung adoption and growing interest in early lung cancer diagnostic tools.
Medical Devices & Diagnostics

Why bioAffinity’s CyPath Lung growth still leaves investors facing a hard cash question

CyPath Lung is gaining clinical traction. The harder test is whether bioAffinity can scale adoption before cash pressure tightens.

Read More
Representative image: Kanvas Biosciences’ Gates Foundation-backed microbiome therapy program highlights how synthetic live biotherapeutics could target maternal environmental enteric dysfunction, a gut disorder linked to undernutrition, low birthweight and newborn health risks in Southern Asia and Sub-Saharan Africa.
Pharma & Biotech

Can Kanvas Biosciences turn microbiome replacement into a maternal health intervention?

Maternal EED lacks scalable therapies. Kanvas Biosciences now faces the harder test: proving microbiome replacement can work where need is greatest.

Read More
Representative image: A pediatric neurology research setting highlights the clinical and regulatory stakes behind Actio Biosciences’ KYRON trial of ABS-1230 for KCNT1-related epilepsy, as precision medicine developers seek new treatment pathways for ultra-rare genetic seizure disorders.
Pharma & Biotech

Could Actio’s KCNT1 epilepsy drug become an ultra-rare disease test case for the FDA?

Ultra-rare epilepsy has few paths forward. Actio’s ABS-1230 now tests whether precision genetics can reshape FDA evidence standards.

Read More